Journal: NPJ Precision Oncology

Article Title: Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer

doi: 10.1038/s41698-021-00204-0

Figure Lengend Snippet: a 3T3 cells expressing FGFR variants, GFP, EGFR L858R, and KRAS G12V were treated with DMSO or FGFR-targeted drugs (AZD4547, infigratinib, E7090, erdafitinib, futibatinib, pemigatinib, and dovitinib) at the indicated concentrations. The relative viability of the treated cells with each drug versus DMSO-treated cells was measured, and the results are illustrated using the color-coded scale. b 3T3 cells with FGFR2 variants or KRAS G12V were incubated with the indicated concentrations of inhibitors for 5 days. Cell viability was measured using the PrestoBlue cell viability assay and plotted relative to the untreated control. Data are presented as mean ± SD ( n = 6). The IC 50 values of inhibitors are shown in the table at the bottom. The p -value in the comparison of IC 50 between each two variants is shown in Supplementary Data . c Inhibition of phosphorylation of FGFR and downstream pathway by E7090 and erdafitinib. 3T3 cells with FGFR variants were treated with E7090 or erdafitinib for 2 h, and whole-cell lysate were analyzed by western blotting using antibodies against FGFR2, FGFR3, phospho-FGFR (p-FGFR, Tyr653/654), p44/42 MAPK, phospho-p44/42 MAPK (p-MAPK, Thr202/204), and β-Actin. WT wild-type, EC extracellular domain, TM transmembrane domain, TK tyrosine kinase domain.

Article Snippet: All inhibitors used in the assay, except E7090 (provided from Eisai Co., Ltd., Tokyo, Japan), were commercially purchased: dovitinib, AZD4547, infigratinib, pemigatinib (all from MedChem Express, Monmouth Junction, NJ, USA), futibatinib (Cayman Chemical, Ann Arbor, MI, USA), and erdafitinib and H3B-6527 (both from Selleckchem, Houston, TX, USA).

Techniques: Expressing, Incubation, Viability Assay, Inhibition, Western Blot

Journal: NPJ Precision Oncology

Article Title: Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer

doi: 10.1038/s41698-021-00204-0

Figure Lengend Snippet: a 3T3 cells expressing FGFR variants, GFP, EGFR L858R, and KRAS G12V were treated with DMSO or FGFR-targeted drugs (AZD4547, infigratinib, E7090, erdafitinib, futibatinib, pemigatinib, and dovitinib) at the indicated concentrations. The relative viability of the treated cells with each drug versus DMSO-treated cells was measured, and the results are illustrated using the color-coded scale. b 3T3 cells with FGFR2 variants or KRAS G12V were incubated with the indicated concentrations of inhibitors for 5 days. Cell viability was measured using the PrestoBlue cell viability assay and plotted relative to the untreated control. Data are presented as mean ± SD ( n = 6). The IC 50 values of inhibitors are shown in the table at the bottom. The p -value in the comparison of IC 50 between each two variants is shown in Supplementary Data . c Inhibition of phosphorylation of FGFR and downstream pathway by E7090 and erdafitinib. 3T3 cells with FGFR variants were treated with E7090 or erdafitinib for 2 h, and whole-cell lysate were analyzed by western blotting using antibodies against FGFR2, FGFR3, phospho-FGFR (p-FGFR, Tyr653/654), p44/42 MAPK, phospho-p44/42 MAPK (p-MAPK, Thr202/204), and β-Actin. WT wild-type, EC extracellular domain, TM transmembrane domain, TK tyrosine kinase domain.

Article Snippet: All inhibitors used in the assay, except E7090 (provided from Eisai Co., Ltd., Tokyo, Japan), were commercially purchased: dovitinib, AZD4547, infigratinib, pemigatinib (all from MedChem Express, Monmouth Junction, NJ, USA), futibatinib (Cayman Chemical, Ann Arbor, MI, USA), and erdafitinib and H3B-6527 (both from Selleckchem, Houston, TX, USA).

Techniques: Expressing, Incubation, Viability Assay, Inhibition, Western Blot